Precision Biosciences Inc(DTIL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DTIL Precision Biosciences Inc

交易中 07-15 12:30:31 EDT

8.68

+0.10

+1.17%

最高8.79	最低8.01	成交量29.34万
今开8.58	昨收8.58	日振幅9.09%
总市值2.24亿	流通市值2.08亿	总股本2,580万
成交额248.27万	换手率1.22%	流通股本2,396万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DTIL","market":"US","secType":"STK","nameCN":"Precision Biosciences Inc","latestPrice":8.68,"timestamp":1784133002807,"preClose":8.58,"halted":0,"volume":293412,"delay":0,"changeRate":0.011655011655011614,"floatShares":23957431,"shares":25803200,"eps":-3.6671,"marketStatus":"交易中","change":0.1,"latestTime":"07-15 12:30:31 EDT","open":8.58,"high":8.79,"low":8.01,"amount":2482690.673988,"amplitude":0.090909,"askPrice":8.73,"askSize":200,"bidPrice":8.68,"bidSize":55,"shortable":3,"etf":0,"ttmEps":-3.6671,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784145600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1553745600000,"exchange":"NASDAQ","adjPreClose":8.58,"preHourTrading":{"tag":"盘前","latestPrice":8.5,"preClose":8.58,"latestTime":"08:40 EDT","volume":12,"amount":103.19999999999999,"timestamp":1784119246041,"change":-0.08,"changeRate":-0.009324,"amplitude":0.052448},"postHourTrading":{"tag":"盘后","latestPrice":8.58,"preClose":8.58,"latestTime":"16:55 EDT","volume":5335,"amount":45768.86,"timestamp":1784062547476,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.932723,"impliedVol":1.0135,"impliedVolPercentile":0.3953},"requestUrl":"/m/hq/s/DTIL/wiki","defaultTab":"wiki","newsList":[{"id":"1134841500","title":"Precision Biosciences 预计在2026年底前获得Function-DMD试验初步安全性数据 - 根据SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1134841500","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134841500?lang=zh_cn&edition=full","pubTime":"2026-07-01 19:19","pubTimestamp":1782904757,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，生物技术公司Precision Biosciences Inc（简称：Precision）预计将在2026年底前获得其针对杜氏肌营养不良症（DMD）的基因编辑疗法Function-DMD临床试验的初步安全性数据。该文件明确了这一关键里程碑的时间目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103915712","title":"精准生物科学公司宣布纳入罗素2000®指数，提升机构投资者市场关注度","url":"https://stock-news.laohu8.com/highlight/detail?id=1103915712","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103915712?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:03","pubTimestamp":1782730996,"startTime":"0","endTime":"0","summary":"精准生物科学公司宣布，其股票已被纳入备受瞩目的罗素2000®指数。这一重要里程碑预计将显著提升公司在机构投资者群体中的市场能见度与认知度，为未来的增长与融资活动创造更有利的条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181457174","title":"Precision BioSciences与加州银行签署贷款及担保协议第一修正案","url":"https://stock-news.laohu8.com/highlight/detail?id=1181457174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181457174?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:04","pubTimestamp":1781640252,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件显示，Precision BioSciences公司已与加州银行就其贷款及担保协议签署了第一修正案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138968","title":"Precision BioSciences即将发布一季报 市场关注营收表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138968","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633138968?lang=zh_cn&edition=full","pubTime":"2026-05-05 03:12","pubTimestamp":1777921920,"startTime":"0","endTime":"0","summary":"临床阶段基因编辑公司Precision BioSciences将于周二盘前发布2026年第一季度财报，随后于上午9：30召开电话会议。　　根据市场预期，分析师预计公司Q1每股亏损为0.655至0.81美元，营收约为405万美元。　　回顾上一季度，公司业绩表现分化：2025年第四季度营收达3420万美元，远超市场预期的907.5万美元，但主要得益于一次性里程碑付款。　　近期内部人士交易引发关注：CEO Michael Amoroso和CFO John Alexander Kelly于2月18日分别减持20，559股和8，149股，均价3.84美元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-05/doc-inhwunrt0079040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106140224","title":"精准生物科技启动首个临床试验中心并开启功能型杜氏肌营养不良1/2期研究患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1106140224","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106140224?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:04","pubTimestamp":1777460643,"startTime":"0","endTime":"0","summary":"精准生物科技公司已正式启动其首个临床试验中心，并开始为功能型杜氏肌营养不良症（Function-Dmd）的1/2期研究招募患者。这一关键进展标志着公司针对该罕见病的新型基因疗法正式进入临床验证阶段。\n此次启动的临床试验旨在评估创新疗法的安全性与有效性，为后续研究奠定基础。患者招募工作的启动意味着符合条件的个体将有机会参与这项前沿医学研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197780779","title":"Precision BioSciences将在2026年美国基因与细胞治疗学会(ASGCT)年会上进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1197780779","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197780779?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374159,"startTime":"0","endTime":"0","summary":"Precision BioSciences公司宣布，其研究成果已获选在2026年美国基因与细胞治疗学会（ASGCT）年度会议上进行口头报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165245779","title":"Precision BioSciences 在欧盟两国临床试验申请获批后扩大 Eliminate-B 试验规模","url":"https://stock-news.laohu8.com/highlight/detail?id=1165245779","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165245779?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:02","pubTimestamp":1776250942,"startTime":"0","endTime":"0","summary":"生物技术公司 Precision BioSciences 宣布，其针对B细胞恶性肿瘤的CAR-T疗法候选药物 Eliminate-B 的临床试验申请已获得两个欧洲国家的监管批准。基于此项进展，公司决定扩展该项临床试验的覆盖范围。此次扩展将有助于加速该疗法的全球开发进程，并为更多患者提供参与前沿治疗研究的机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100858936","title":"Precision BioSciences公布2025财年第四季度及全年业绩，并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100858936","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100858936?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:01","pubTimestamp":1773313293,"startTime":"0","endTime":"0","summary":"Precision BioSciences Inc（纳斯达克代码：DTIL）近日公布了其2025财年第四季度及全年的财务业绩报告，同时向市场同步了公司最新的业务发展动态。此次披露涵盖了公司在指定时期内的关键财务数据与运营里程碑，为投资者提供了全面的业绩概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139226896","title":"Precision BioSciences 旗下基因疗法Pbgene-Dmd获FDA快速通道资格，并将举办杜氏肌营养不良症投资者交流会","url":"https://stock-news.laohu8.com/highlight/detail?id=1139226896","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139226896?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:04","pubTimestamp":1773054299,"startTime":"0","endTime":"0","summary":"生物技术公司Precision BioSciences宣布，其用于治疗杜氏肌营养不良症（DMD）的研究性基因疗法Pbgene-Dmd已获得美国食品药品监督管理局（FDA）授予的快速通道资格。\n此项认定旨在加速针对严重疾病且具有未竟医疗需求的新药的开发和审评进程。与此同时，公司还计划举办一场专门的投资者活动，重点介绍Pbgene-Dmd项目的进展与前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180002087","title":"Precision BioSciences获TG Therapeutics支付750万美元，用于Azer-Cel在多发性硬化症临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1180002087","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180002087?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:03","pubTimestamp":1772453001,"startTime":"0","endTime":"0","summary":"生物技术公司Precision BioSciences Inc宣布，其合作伙伴TG Therapeutics已向其支付750万美元，作为Azer-Cel疗法在多发性硬化症临床研发中达成重要里程碑的款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610596407","title":"Precision Biosciences, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610596407","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610596407?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:30","pubTimestamp":1770820240,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日22时30分，Precision Biosciences, Inc.股票出现异动，股价大幅上涨5.05%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Pmgc Holdings Inc.、Quince Therapeutics, Inc.、Phio Pharmaceuticals Corp.涨幅较大，Pmgc Holdings Inc.、Quince Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1626.08%、221.92%、175.25%，振幅较大的相关个股有Tuhura Biosciences, Inc.、Quince Therapeutics, Inc.、Veru Inc.，振幅分别为13.85%、11.39%、7.79%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台 ARCUS 改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211223040a4987b9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211223040a4987b9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117918532","title":"Precision BioSciences获美国FDA批准杜氏肌营养不良症首创疗法Pbgene-Dmd的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1117918532","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117918532?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:05","pubTimestamp":1770811522,"startTime":"0","endTime":"0","summary":"Precision BioSciences公司宣布，其针对杜氏肌营养不良症（DMD）的首创基因疗法Pbgene-Dmd，已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）申请批准。这一重要监管里程碑为该疗法进入临床研究阶段铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120753377","title":"Empery资产管理公司申报被动持股Precision BioSciences达9.99%（截至2025年12月31日）","url":"https://stock-news.laohu8.com/highlight/detail?id=1120753377","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120753377?lang=zh_cn&edition=full","pubTime":"2026-01-23 02:07","pubTimestamp":1769105232,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件，截至2025年12月31日，Empery资产管理有限公司（Empery Asset Management Lp）已持有生物科技公司Precision BioSciences Inc（简称：Precision BioSciences）9.99%的被动股权。该持股比例已接近10%的申报门槛，反映出机构投资者对Precision BioSciences业务前景的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516608738","title":"Precision Biosciences, Inc.盘中异动 早盘急速下跌6.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516608738?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:52","pubTimestamp":1741099964,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时52分，Precision Biosciences, Inc.股票出现异动，股价快速下跌6.20%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1138.13%、1113.66%、512.36%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Celularity Inc C/Wts 16/07/2026 、Nutriband Inc C/Wts ，振幅分别为44.32%、37.67%、25.66%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225244a25f0b4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225244a25f0b4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516373896","title":"Precision Biosciences, Inc.盘中异动 早盘急速下挫5.19%报5.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516373896","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516373896?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:44","pubTimestamp":1741013046,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时44分，Precision Biosciences, Inc.股票出现波动，股价快速跳水5.19%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Aldeyra Therapeutics, Inc.涨幅较大，Entero Therapeutics Inc.、Allarity Therapeutics, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为99.25%、52.61%、41.29%，振幅较大的相关个股有Entero Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为55.45%、24.83%、22.27%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224406989a132a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224406989a132a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514373829","title":"Precision Biosciences, Inc.盘中异动 股价大跌5.37%报5.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514373829?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:54","pubTimestamp":1740754466,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时54分，Precision Biosciences, Inc.股票出现波动，股价大幅下跌5.37%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为595.45%、362.72%、301.64%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Enveric Biosciences, Inc.，振幅分别为45.32%、35.13%、29.25%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225427a2580738&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225427a2580738&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514016807","title":"Precision Biosciences, Inc.盘中异动 股价大跌6.75%报5.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514016807?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:27","pubTimestamp":1740497233,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时27分，Precision Biosciences, Inc.股票出现波动，股价急速下挫6.75%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1063.71%、905.72%、592.63%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、64.05%、61.16%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232713962fff48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232713962fff48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513720877","title":"Precision Biosciences, Inc.盘中异动 大幅跳水5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720877","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513720877?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:00","pubTimestamp":1740409201,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时00分，Precision Biosciences, Inc.股票出现波动，股价大幅下跌5.40%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Avalo Therapeutics, Inc.涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为151.23%、65.89%、25.12%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230001a2521b65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230001a2521b65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511696450","title":"Precision Biosciences, Inc.盘中异动 急速拉升5.43%报5.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511696450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511696450?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:33","pubTimestamp":1739543631,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时33分，Precision Biosciences, Inc.股票出现异动，股价快速拉升5.43%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Virpax Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为1063.55%、373.27%、342.34%，振幅较大的相关个股有Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Virpax Pharmaceuticals, Inc.、Theratechnologies Inc.，振幅分别为20.20%、19.73%、18.33%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223351a2460191&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223351a2460191&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DTIL","BK4007","VRPX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508457645","title":"Precision Biosciences, Inc.盘中异动 早盘股价大涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508457645","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508457645?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:31","pubTimestamp":1738679510,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时31分，Precision Biosciences, Inc.股票出现异动，股价快速上涨5.31%。Precision Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，Azitra Inc、Evaxion Biotech As、Invivyd, Inc.涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为863.36%、681.80%、185.86%，振幅较大的相关个股有Azitra Inc、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 、Omega Therapeutics, Inc.，振幅分别为25.13%、19.74%、18.97%。Precision Biosciences, Inc.公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223150a23928c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223150a23928c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DTIL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.precisionbiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0724},{"period":"1month","weight":0.4066},{"period":"3month","weight":0.1201},{"period":"6month","weight":1.2},{"period":"1year","weight":0.8491},{"period":"ytd","weight":1.0625}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Precision BioSciences, Inc.于2006年1月在特拉华州注册成立。该公司是一家临床阶段的基因编辑公司，利用其专有的ARCUS平台开发体内基因编辑疗法。其平台专为基因插入、消除和切除等复杂编辑而设计，利用其独特的切割特性和更小的尺寸来实现明确的治疗结果。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006651},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086823},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.150968},{"month":4,"riseRate":0.5,"avgChangeRate":-0.028297},{"month":5,"riseRate":0.5,"avgChangeRate":-0.002372},{"month":6,"riseRate":0.375,"avgChangeRate":-0.027676},{"month":7,"riseRate":0.375,"avgChangeRate":-0.032253},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.015387},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.072792},{"month":10,"riseRate":0.428571,"avgChangeRate":0.004662},{"month":11,"riseRate":0.428571,"avgChangeRate":0.33136},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.221276}],"exchange":"NASDAQ","name":"Precision Biosciences Inc","nameEN":"Precision Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Precision Biosciences Inc(DTIL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Precision Biosciences Inc(DTIL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Precision Biosciences Inc,DTIL,Precision Biosciences Inc股票,Precision Biosciences Inc股票老虎,Precision Biosciences Inc股票老虎国际,Precision Biosciences Inc行情,Precision Biosciences Inc股票行情,Precision Biosciences Inc股价,Precision Biosciences Inc股市,Precision Biosciences Inc股票价格,Precision Biosciences Inc股票交易,Precision Biosciences Inc股票购买,Precision Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Precision Biosciences Inc(DTIL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Precision Biosciences Inc(DTIL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}